Here, we seek to identify sex-specific metabolomic biomarkers of dysglycemia over six years of follow-up among general-risk youth in Colorado (the EPOCH study); we also evaluate the extent to which the metabolomic biomarkers improve the prediction of dysglycemia beyond known risk factors (i.e., race/ethnicity, family history of T2D, in utero exposure to gestational diabetes, body mass index) and conventional biomarkers of T2D risk used in research settings (i.e., waist circumference, fasting insulin, lipid profile, pubertal status), and baseline glycemia (fasting glucose). This evidence concerns the gene INS and gestational diabetes.